Pneumococcal (20-valent) vaccine is under clinical development by Suzhou Weichao Biotechnology and currently in Phase I for Sepsis. According to GlobalData, Phase I drugs for Sepsis does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the Pneumococcal (20-valent) vaccine LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Pneumococcal (20-valent) vaccine overview
Vaccine is under development for the prevention of Streptococcal pneumonia infections, meningitis and sepsis caused by pneumococcal serotypes 1, 3, 4, 5, 6A, 6B, 7F, 8, 9V, 10A, 11A, 12F, 14, 15B, 18C, 19A, 19F, 22F, 23F, and 33F. It is a 20-valent conjugated vaccine. It is administered through intramuscular route.
Suzhou Weichao Biotechnology overview
Suzhou Weichao Biotechnology (Weichao Biotechnology) operate in healthcare sector. Weichao Biotechnology is headquartered in Suzhou, Jiangsu, China.
For a complete picture of Pneumococcal (20-valent) vaccine’s drug-specific PTSR and LoA scores, buy the report here.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.